Listen to this story



Drug developed to stop breast cancer metastasis.

Glendy Narea
2 min read

In Spain, some scientists developed an oncological drug that prevents tumor cells from multiplying and metastasizing in breast cancer.

Drug developed to stop breast cancer metastasis. – Health – WebMediums
The drug can block the invasion, growth and establishment of breast cancer metastasis

The medicine, whose name is Omomyc, was created at the Hospital de la Vall d'Hebron, in Barcelona, Spain. The effect obtained with the study has been described as "very positive".

The protein it contains acts in the human body, stopping the MYC gene, which is the cause of the development of most solid tumors.

The veracity of this drug was tested on primary tumors, which had not yet spread throughout the body. After this, it was possible to verify its usefulness in cases of metastasis, when the disease has spread from one organ to another, thus hindering possible recovery.

The EFE news agency interviewed Daniel Massó, researcher and creator of the product, who explained that "the response has been very positive and in all cases it has been possible to verify that Omomyc has significant antimetactic activity against what had been speculated".

Antitumor, Laura Soucek, highlighted the effectiveness of the drug, since it is capable of blocking the invasion, growth and establishment of breast cancer metastasis.

Omomyc, according to research, produces a high response that totally eliminates the tumor, generating an "immune memory". This means that the immune system is previously prepared and trained to block a possible relapse as a result of the disease.

The drug may not yet be acquired by all patients

Doctors reported that there are still a few years to go before this medicine reaches all patients and also complies with the respective safety regulations.

The innovative drug has already passed all preclinical tests. Currently, the first phase clinical I trial is beginning, where they will test 40 patients who are being treated with LIF inhibitors at the Vall d'Hebron Hospital (Barcelona), the Princess Margaret (Toronto, Canada) and the Sloan Ketterng (New York, USA).